User profiles for G. F. Ferraccioli
g ferraccioliProfessor of Rheumatology, Universita' Cattolica del Sacro Cuore, Roma Verified email at unicatt.it Cited by 40306 |
Preliminary classification criteria for the cryoglobulinaemic vasculitis
Background To develop preliminary classification criteria for the cryoglobulinaemic syndrome
or cryoglobulinaemic vasculitis (CV). Methods Study part I developed a questionnaire for …
or cryoglobulinaemic vasculitis (CV). Methods Study part I developed a questionnaire for …
Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.
… GF Ferraccioli, Catholic University of the Sacred Heart, Association Columbus, Via Moscati
31, 00168, Rome, Italy. E-mail:gf.ferraccioli@… Welsing PM, Borm GF, Van Riel PLCM. Minimal …
31, 00168, Rome, Italy. E-mail:gf.ferraccioli@… Welsing PM, Borm GF, Van Riel PLCM. Minimal …
[HTML][HTML] Arthritis in systemic lupus erythematosus: from 2022 International GISEA/OEG symposium
…, R Caporali, M Sebastiani, GF Ferraccioli… - Journal of clinical …, 2022 - mdpi.com
Musculoskeletal involvement is one of the most common manifestations of systemic lupus
erythematosus (SLE), with a negative impact on both quality of life and overall prognosis. SLE …
erythematosus (SLE), with a negative impact on both quality of life and overall prognosis. SLE …
General and specific factors associated with severity of cognitive impairment in systemic lupus erythematosus
…, G La Torre, S De Vita, GF Ferraccioli - Arthritis Care & …, 2007 - Wiley Online Library
Objective To determine factors affecting the severity of cognitive impairment in systemic
lupus erythematosus (SLE) and to analyze its anatomic location. Methods Fifteen cognitive …
lupus erythematosus (SLE) and to analyze its anatomic location. Methods Fifteen cognitive …
Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial
JS Smolen, P Emery, GF Ferraccioli… - Annals of the …, 2015 - ard.bmj.com
Objectives This 52-week, randomised, double-blind phase IIIb study assessed efficacy and
safety of certolizumab pegol (CZP) as add-on therapy to non-biologic disease-modifying …
safety of certolizumab pegol (CZP) as add-on therapy to non-biologic disease-modifying …
Proteomic study of salivary peptides and proteins in patients with Sjögren's syndrome before and after pilocarpine treatment
…, M Castagnola, GF Ferraccioli - … : Official Journal of …, 2007 - Wiley Online Library
Objective. To investigate the effect of pilocarpine on the salivary peptide and protein profile
in patients with primary Sjögren’s syndrome (SS) and to study the differences between …
in patients with primary Sjögren’s syndrome (SS) and to study the differences between …
TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis
…, C Di Campli, R Flore, P Tondi, GF Ferraccioli - Clinical …, 2008 - Springer
Considerable evidence indicates that patients with rheumatoid arthritis (RA) are at greater
risk of developing atherosclerosis and cardiovascular disease. Recent studies support the …
risk of developing atherosclerosis and cardiovascular disease. Recent studies support the …
[PDF][PDF] Benefit/risk of cyclosporine in rheumatoid arthritis
E Gremese, GF Ferraccioli - Clinical and experimental …, 2004 - researchgate.net
Combination therapy has emerged as a crucial therapeutic tool to control aggressive rheumatoid
arthritis (RA). Cyclosporine (CsA) when combined with methotrexate (MTX) has shown …
arthritis (RA). Cyclosporine (CsA) when combined with methotrexate (MTX) has shown …
Synovial fluid-derived T helper 17 cells correlate with inflammatory activity in arthritis, irrespectively of diagnosis
We analyzed peripheral blood (PB) and synovial fluid (SF) mononuclear cells from 16
rheumatoid arthritis (RA), 9 spondyloarthritis (SpA), 3 microcrystal arthritis patients, to define the …
rheumatoid arthritis (RA), 9 spondyloarthritis (SpA), 3 microcrystal arthritis patients, to define the …
Combined treatment with renin–angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial
PM Ferraro, GF Ferraccioli, G Gambaro… - Nephrology Dialysis …, 2009 - academic.oup.com
Background. Currently, several therapeutic protocols exist for IgA nephropathy (IgAN);
results in slowing the progression to end-stage renal disease (ESRD) are variable, but ∼30–40% …
results in slowing the progression to end-stage renal disease (ESRD) are variable, but ∼30–40% …